Remember, natural gas isn’t just for heating; air conditioning demand sends natural gas for August delivery up 10.2% today
There are the base-load power plants that run all the time and meet the bulk of normal electricity demand. And then there are the power plants that are only intermittently called into service when demand spikes. In the United States the majority of the plants used to...
Adding Invesco Dollar Bullish Fund ETF to three portfolios
In my July 7 YouTube video: “Quick Pick UUP” I added the Invesco DB U.S. Dollar Index Bullish Fund (UUP) to my Perfect 5 ETF Portfolio. (To replace the Consumer Staples Select Sector SPDR ETF (XLP) in that portfolio. More on that in another post today.)...
Watch my new YouTube video: QuickPick: EVGO for fast charging
I’m starting up my videos again–this time using YouTube as a platform. The thirty-third YouTube video “QuickPick: EVGO for fast charging” went up today. Please watch and subscribe to my YouTube channel. And like my video. You can see it...
Take what the market is giving you: Three short-term moves for short-and mid-term gains
The one certainty in the stock market right now, I’d say, is volatility. Both to the upside and to the downside. So I think we should take what the market is giving us. Using these three moves in the short term. 1. Buy a few buy on the dip candidates from my...
Doing a little selling to raise some cash for potential bargains: Selling Invesco Yen ETF, JD.Com, and Vanguard Treasury ETF
Let’s be clear. I don’t have any idea of when the current selling in technology and high-valuation growth momentum stocks will end. It does seem likely to me, even after the March 9 bounce, that the rotation into cyclicals, vaccine recovery stocks, and...
In a bear market panic, it’s really, really hard to figure which way stocks will jump on any particular day.
Yesterday, I sold my Put options on Nvidia (NVDA) and Apple (AAPL) with gains of around 100% in each since I added them to my Volatility Portfolio (on my subscription JugglingwithKnives.com and JubakAM.com sites) on March 10. I’d bought those Puts in order to...
Should you follow Wall Street’s advice de l’annee for 2020 into emerging market stocks?
Jim’s Extras are something new that I’ve added to JubakPicks.com. Jim’s Extras are posts that provide a wider economic or market analysts than the normal diet here of stock specific posts or posts that cover the day’s market moves. Like...
So how’s my “Tech is back” call (and picks of SWKS and CRUS) doing?
On October 8 I wrote “Tech is back” led by fact-based speculation that Apple (AAPL) had asked supplier to increase production of components for the iPhone 11 by 10%. That, obviously, was a good sign for Apple, which is set to announce earnings on October...
Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
Making Incyte #9 on my 10 most dangerous stocks for earnings season list–and #5 on my buy on any plunge list
Today on my JubakAM.com subscription site I made Incyte #9 in my 10 Most dangerous Stocks for Earnings Season Special Report–and #5 on my Buy on Any Plunge Bonus Special Report. Here’s what I wrote: “There’s a good chance that Incyte (INCY)...
Adding yen exposure to Jubak Picks and Volatility Portfolios
On December 27 I switched to the Invesco Currency Shares Japanese Yen ETF (FXY) from the Vanguard FTSE Developed Markets ETF (VEA) in my Perfect 5 ETF Portfolio (on my subscription sites JugglingWithKnives.com and JubakAM.com) in an effort to get more yen exposure...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
It’s never good to turn in disappointing results in a drug trial–as Nektar Therapeutics (NKTR) did over the weekend–but to whack 40% off the stock price on this news is an extreme over-reaction. To justify a 40% drop you have to assume 1) that the...
Book keeping changes: Statoil (STO) changes its name and ticker to Equinor (EQNR)
A change in the name and ticker of portfolio holding Statoil (STO). The explanation offered by the company is that it wanted to remove “oil” from its name to better reflect the company’s increasing emphasis on other forms of energy including wind...
Ignore the short-term oil volatility and continue to hold Pioneer Natural Resources for the long-term story
So much near-term noise. Since Pioneer Natural Resources (PXD) reported earnings on May 2–the company beat Wall Street estimates on earnings by 16 cents a share and reported revenue in-line with projections and up 56.5% year over year–there’s been...
Little spillover (yet) from Concho acquisition of Permian producer RSPP
Today Concho Resources (CXO) announced the acquisition of RSP Permian (RSPP) to create the biggest oil and natural gas producer from the shales of the Permian Basin. The $9.5 billion all stock deal represents a 29% premium to the Tuesday close for RSP Permian. That...
How to manage risk in this market when the traditional risk safe havens aren’t working
If you spend a significant part of your day staring at your computer to watch the markets, you know that, perplexingly, the traditional safe havens for mitigating portfolio risk haven’t been working very well. For example, gold, which is supposed to go up when...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Big earnings report from MGM Resorts before the market open tomorrow
Tomorrow’s earnings report from MGM Resorts International (MGM) could be make or break for the call options that I hold on this stock in my Volatility Portfolio. The options have been all over the block in recent weeks from up 50% to down 30% on market...
On my JubakAM.Com subscription site, I just added an ETF for the bond bear market–and today’s meltdown
The logic is pretty simple–I think the rise in yields on Treasuries and the anticipated rise in interest rates from the Federal Reserve that sent the Dow Jones Industrial Average down more than 650 points today isn’t over. There’s just too much...
Hey, the Groundhog has an offer you can’t refuse–on a portfolio that made 53% in 2017
I just finished my performance report on my Volatility Portfolio of stocks, options, and ETFs, and for the first year of its operation the portfolio was up 53%. In honor of Groundhog’s Day I’m offering a 20% discount on my JubakAM.com site, the home of...
Adding Caterpillar to my Jubak Picks and Volatility Portfolios ahead of earnings tomorrow
Caterpillar (CAT) looks to be a major beneficiary of the lower tax rates in the Tax Cuts & Jobs Act and for a lower U.S. dollar. (See today’s encouragement of a weaker dollar from Treasury Secretary Steve Mnuchin at Davos today.) Not that Caterpillar sales...
Nektar soars today on J.P. Morgan healthcare conference
Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech...
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year’s gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid...
Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say “Buy” in Jubak Picks even after this run
Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to...
My last post setting up my new Perfect 5 ETF Portfolio–and your last chance to get 2 weeks free and then 20% off a subscription
I’ve named the five ETFs in this portfolio. Explained my ideas on allocation money among those five ETFs and their associated asset classes. And discussed the importance of knowing what index an ETF follows. Now it’s time to explain one last thing to...
Facebook reports big gain in number of advertisers in run up to earnings
Facebook (FB) Chief Operating Officer Sheryl Sandberg told Reuters that the company now had 5 million active advertisers on its network each month. That’s up from 4 million advertisers in September and 3 million in March 2016. The number of businesses with...
Here’s what I’ve been writing about on my paid sites: Biotech stocks dipping just before medical meeting schedule gets heavy
Let me share a post about a trading opportunity that I put up today on my paid sites. Yes, that’s sites. Plural. I’ve been busy building a second site, JugglingWithKnives.com, that parallels the focus of my book Juggling With Knives on volatility. If you...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!